Earnings summaries and quarterly performance for Dianthus Therapeutics, Inc. /DE/.
Executive leadership at Dianthus Therapeutics, Inc. /DE/.
Marino Garcia
Detailed
Chief Executive Officer and President
CEO
AV
Adam Veness
Detailed
Senior Vice President, General Counsel and Secretary
EC
Edward Carr
Detailed
Chief Accounting Officer
RS
Ryan Savitz
Detailed
Chief Financial Officer, Chief Business Officer and Treasurer
SR
Simrat Randhawa
Detailed
Chief Medical Officer
Board of directors at Dianthus Therapeutics, Inc. /DE/.
AL
Alison Lawton
Detailed
Independent Chair of the Board
AM
Anne McGeorge
Detailed
Independent Director
JV
Jonathan Violin
Detailed
Independent Director
PS
Paula Soteropoulos
Detailed
Independent Director
SR
Simon Read
Detailed
Director
SR
Steven Romano
Detailed
Independent Director
SK
Sujay Kango
Detailed
Independent Director
Research analysts covering Dianthus Therapeutics, Inc. /DE/.
Recent press releases and 8-K filings for DNTH.
Dianthus Therapeutics Provides Updates on Claseprubart Clinical Programs and Timelines
DNTH
New Projects/Investments
Guidance Update
- Dianthus Therapeutics expects to announce interim responder analysis for its Phase III CIDP trial (CAPTIVATE study) in Q2 2026. The company notes accelerated recruitment for this trial.
- Top-line results from the Phase II MMN trial are anticipated in the second half of 2026.
- Management indicated that strong efficacy of the 300 mg dose of claseprubart in the CIDP trial could lead to a one-third reduction in the Phase III trial size, accelerating time to market.
- The company addressed theoretical risks of drug-induced lupus-like symptoms (DILS), clarifying that C1s inhibitors like claseprubart have not shown these issues, unlike C1q inhibitors, and that their drug only inhibits activated C1s.
19 hours ago
Dianthus Therapeutics Outlines Key Milestones and Financial Position
DNTH
New Projects/Investments
Guidance Update
- Dianthus Therapeutics anticipates key clinical catalysts in 2026 for its lead program, clasiprubart, including CIDP phase 3 Part A interim responder analysis in Q2 2026 and MMN phase 2 top-line results in H2 2026.
- For DNTH212, the company expects to announce three target indications in H1 2026 and top-line results from a healthy volunteer study in H2 2026.
- The company projects clasiprubart peak sales to exceed $5 billion over the long run, driven by potential advantages in efficacy, safety, and convenience across MG, CIDP, and MMN indications.
- Dianthus Therapeutics reported ending 2025 with $514 million in cash, which is expected to fund operations into 2028 and cover significant upcoming milestones.
Feb 12, 2026, 3:00 PM
Dianthus Therapeutics Highlights Key Program Milestones and Strong Cash Position
DNTH
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Dianthus Therapeutics anticipates several key catalysts in 2026 for its lead program, clasiprubart, including CIDP phase 3 interim responder analysis in Q2 2026 and MMN phase 2 top-line results in H2 2026.
- For DNTH212, the company expects to announce three target indications in H1 2026 and top-line results from a healthy volunteer study in H2 2026.
- The company ended 2025 with $514 million in cash, providing a financial runway into 2028 and covering significant program milestones.
- Management projects clasiprubart peak sales could exceed $5 billion over the long term, driven by potential advantages in efficacy, safety, and convenience across Myasthenia Gravis (MG), CIDP, and MMN indications.
Feb 12, 2026, 3:00 PM
Dianthus Therapeutics Outlines Key Clinical Catalysts and Financial Position
DNTH
New Projects/Investments
Guidance Update
- Dianthus Therapeutics anticipates several key clinical catalysts in 2026 and 2027, including interim responder analysis for its CIDP Phase 3 study in Q2 2026, top-line Phase 2 results for MMN in H2 2026, and clarity on DNTH212 indications in H1 2026.
- The company's lead program, clasiprubart, is positioned for potential market advantages in CIDP, MMN, and MG due to its potency, convenient dosing (sub-Q auto-injector), and anticipated lack of a box warning compared to competitors.
- Management projects clasiprubart peak sales could exceed $5 billion over the long run, with significant contributions from the MG market alone estimated at $2-$4 billion.
- Dianthus Therapeutics reported a strong financial position, ending the year with $514 million in cash, providing runway into 2028 and covering upcoming milestones for both clasiprubart and DNTH212.
Feb 12, 2026, 3:00 PM
Dianthus Therapeutics Updates on Clinical Programs and Financial Outlook
DNTH
New Projects/Investments
Guidance Update
- Dianthus Therapeutics is advancing two clinical-stage autoimmune therapeutics: claseprubart and DNTH212.
- For claseprubart, the company anticipates announcing interim responder analysis for its CIDP Phase 3 Part A in Q2 2026 and top-line results for its MMN Phase 2 in H2 2026. The Phase 3 trial for MG is also expected to commence soon.
- The second program, DNTH212, has initiated its Phase 1 clinical trial, with healthy volunteer data projected for H2 2026 and data in SLE patients from Part B of Phase 1 expected in 2027.
- Dianthus Therapeutics reports a cash position of $514 million, which is expected to provide a financial runway well into 2028.
Jan 12, 2026, 11:00 PM
Dianthus Therapeutics Provides Updates on Clinical Programs and Financial Runway
DNTH
New Projects/Investments
Guidance Update
- Dianthus Therapeutics (DNTH) reported $514 million in cash, providing a runway well into 2028.
- For Clasibobart, an interim responder analysis for the CIDP Phase 3 trial is expected in early Q2 2026, and top-line results for the MMN Phase 2 trial are anticipated in H2 2026.
- The company plans to initiate a Phase 3 trial for Clasibobart in Myasthenia Gravis (MG) as soon as possible in 2026, which will include testing both every two-week and every four-week dosing schedules.
- Dianthus's second clinical program, DNTH212, a bispecific fusion protein, has commenced its Phase 1 clinical trial, with healthy volunteer data expected in H2 2026.
Jan 12, 2026, 11:00 PM
Dianthus Therapeutics Outlines 2026 Milestones and Cash Runway
DNTH
New Projects/Investments
Guidance Update
- Dianthus Therapeutics is advancing two clinical-stage autoimmune therapeutics, Clasibobart and DNTH212, with several key milestones expected in 2026.
- For Clasibobart, the interim responder analysis for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 3 trial (Part A) is now expected in Q2 2026, and top-line results for the Multifocal Motor Neuropathy (MMN) Phase 2 trial are anticipated in the second half of 2026.
- The company is in discussions with the FDA regarding the Phase 3 trial design for Myasthenia Gravis (MG), aiming for superior efficacy and a patient-friendly dosing schedule.
- DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor, has commenced its Phase 1 clinical trial, with healthy volunteer data expected in the second half of 2026.
- Dianthus Therapeutics reports a strong financial position with approximately $514 million in cash, providing a runway extending well into 2028.
Jan 12, 2026, 11:00 PM
Dianthus Therapeutics, Inc. Provides Financial Update and Announces Positive Phase 2 Results for Claseprubart
DNTH
Guidance Update
New Projects/Investments
- Dianthus Therapeutics, Inc. expects to report approximately $514 million in cash, cash equivalents, and short-term investments as of December 31, 2025, which is projected to provide a financial runway into 2028. This is a preliminary and unaudited estimate.
- The company announced positive Phase 2 results for Claseprubart in generalized Myasthenia Gravis (gMG), demonstrating rapid, sustained, and statistically significant symptom improvements and a potentially differentiated safety profile. The target dose of 300mg/2mL Q2W will be advanced to a Phase 3 study.
- Key upcoming clinical milestones for 2026 include the initiation of a Phase 3 gMG trial for Claseprubart, interim responder analysis for the Phase 3 CIDP trial in Q2 2026, and Phase 2 MMN top-line results in 2H 2026. Additionally, an update on DNTH212 indication prioritization is expected in 1H 2026, with Phase 1 healthy volunteer top-line results in 2H 2026.
Jan 12, 2026, 2:01 PM
Dianthus Therapeutics Highlights De-Risked Profile and Upcoming 2026 Catalysts
DNTH
New Projects/Investments
Guidance Update
- Dianthus Therapeutics is considered a significantly de-risked company following positive Phase II MG data presented in September, which confirmed the potency and safety of its 300 mg every two weeks dosing for neuromuscular conditions.
- The company anticipates two key catalysts in 2026: an interim responder analysis for its CIDP trial in Q2 and Phase II top-line data from its MMN trial in the second half. The CIDP trial timelines were accelerated due to quicker patient enrollment.
- Dianthus has also introduced a new asset, NTH212, a bispecific/bifunctional fusion protein licensed from China, which has potential as a first-in-class and best-in-class product.
- For its CIDP trial, the company expects to see efficacy competitive with riliprubart, with response rates in the 40%-50% range, and is exploring the potential for every four-week dosing in MG.
Dec 2, 2025, 7:35 PM
Dianthus Therapeutics CEO Discusses De-Risked Pipeline and Upcoming Catalysts
DNTH
New Projects/Investments
Guidance Update
- Dianthus Therapeutics (DNTH) has been significantly de-risked following positive Phase 2 MG data in September, which confirmed the potency and safety of claseprubart (300 mg every two weeks) for neuromuscular conditions.
- The company has two significant catalysts in 2026: an interim responder analysis for its CIDP trial in Q2 and Phase 2 top-line data from its MMN trial in H2.
- Recruitment for the CIDP trial accelerated, leading to earlier timelines, and the company expects its drug to show competitive efficacy to riliprubart with a dosing advantage of one shot every two weeks.
- Dianthus also licensed NTH 212, a new bispecific/bifunctional fusion protein with potential as a first-in-class or best-in-class asset, with its indication selection disclosure planned before Phase 1 data in H2 2026.
Dec 2, 2025, 7:35 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more